Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review

被引:0
|
作者
Siddiqui, Muhammad Osama [1 ]
Syed, Mohammad Ali [1 ]
Qureshi, Ayaan Ahmed [1 ]
Imam, Mustafa Hussain [1 ]
Motwani, Jatin [1 ]
Kumari, Verkha [1 ]
Siddiqui, Arooba [2 ]
Ul Ain, Noor [1 ]
Jaber, Mohammed Hammad [3 ]
机构
[1] Liaquat Natl Hosp & Med Coll, Karachi, Pakistan
[2] Karachi Med & Dent Coll, Karachi, Pakistan
[3] Alzaiem Alazhari Univ, Fac Med, Khartoum, Sudan
关键词
THERAPY; COMPLICATIONS; STROKE;
D O I
10.1002/iid3.70122
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionGiant cell arteritis (GCA) is a common vasculitis predominantly affecting larger vessels, especially in individuals aged 70-79. Cerebrovascular ischemic events (CIE), such as stroke and transient ischemic attacks, are serious but rare complications of GCA, with a pooled prevalence of 4%. Some studies found that within 2 weeks of GCA diagnosis, 74% and 34% of patients experience transient or severe ischemic events, respectively.AimsOur study aims to help physicians better manage GCA patients to reduce GCA-related CIE by indicating important risk factors and pharmacological intervention to prevent GCA-related CIE, particularly in the first few days of diagnosis when the risk of CIE is highest.MethodsA comprehensive literature search was conducted using Pubmed, Google Scholar, Scopus, and other relevant medical databases. As this study was a narrative review, the literature search was done in a nonsystematic manner. Studies published from 2000 to 2024 were reviewed in a nonsystematic manner for information on incidence, pathology, risk factors, pharmacological intervention, and management of GCA-related CIE.ResultsFindings indicate that age, male gender, hypertension, and smoking significantly increase the risk of GCA-related CIE, while factors such as anemia, higher body mass index (BMI), and elevated inflammatory markers (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) appear to have protective effects. Symptoms of ischemia in the ophthalmic artery were identified as the strongest predictors of CIE. Pharmacological treatments, including glucocorticoids and tocilizumab, are instrumental in managing and potentially preventing CIE in GCA patients, with adjunctive therapies such as aspirin and antiplatelet agents also showing promise.ConclusionGCA-related CIE such as stroke can be very debilitating and deadly conditions, particularly when GCA is initially diagnosed. However, with early diagnosis and proper management of risk factors, GCA-related CIE can be prevented and its severity can be reduced. Ischemia in the ophthalmic artery is found to strongly predict GCA-related CIE while aspirin and antiplatelet agent during the first 3 months may prevent GCA-related CIE. Risk factors such as BMI and smoking may help in stratifying the risk of GCA-related CIE. This review underscores the importance of further studies with detailed, well-designed approaches to risk factor analysis to strengthen these associations. Identifying these risk factors is crucial for reducing morbidity and mortality, equipping physicians to better assess and mitigate the risk of CIE in GCA patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Prevalence and significance of ischemic cerebrovascular events in giant cell arteritis
    Coronel, Luis
    Rodriguez-Pardo, Jorge
    Monjo, Irene
    de Miguel, Eugenio
    MEDICINA CLINICA, 2021, 157 (02): : 53 - 57
  • [2] Risk factors for severe cranial ischemic events in giant cell arteritis
    Salvarani, Carlo
    Della Bella, Cristina
    Restuccia, Giovanna
    Pipitone, Nicolo
    Ghinoi, Alessandra
    Catanoso, Maria Grazia
    Bajocchi, GianLuigi
    Macchioni, PierLuigi
    Cimino, Luca
    Boiardi, Luigi
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S396 - S396
  • [3] Risk factors for cranial ischemic complications in giant cell arteritis
    Nesher, G
    Berkun, Y
    Mates, M
    Baras, M
    Nesher, R
    Rubinow, A
    Sonnenblick, M
    MEDICINE, 2004, 83 (02) : 114 - 122
  • [4] Extracranial giant cell arteritis: A narrative review
    Lensen, K. D. F.
    Voskuyl, A. E.
    Comans, E. F. I.
    van der Laken, C. J.
    Smulders, Y. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2016, 74 (05): : 182 - 192
  • [5] Risk factors for thrombotic events in giant cell arteritis and polymyalgia rheumatica
    Seriolo, B
    Cutolo, M
    Garnero, A
    Accardo, S
    BRITISH JOURNAL OF RHEUMATOLOGY, 1998, 37 (11): : 1251 - 1253
  • [6] Causes of Cardiovascular Ischemic Events in Giant Cell Arteritis
    Richter, Jutta G.
    Sander, Oliver
    Schneider, Matthias
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (12) : 2092 - 2093
  • [7] Giant Cell Arteritis and Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis
    Ungprasert, Patompong
    Srivali, Narat
    Kittanamongkolchai, Wonngarm
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Risk factors for severe cranial ischaemic events in patients with giant cell arteritis
    Grossman, C.
    Barshack, I.
    Koren-Morag, N.
    Ben-Zvi, I.
    Bornstein, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (01) : S88 - S93
  • [9] An Updated Review of Cardiovascular Events in Giant Cell Arteritis
    de Boysson, Hubert
    Aouba, Achille
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [10] Factors impacting D-dimer levels in patients with acute ischemic cerebrovascular events
    Hacialioglu, Recep-Ali
    Kielkopf, Moritz
    Branca, Mattia
    Clenin, Leander
    Boronylo, Anna
    Silimon, Norbert
    Goldlin, Martina B.
    Scutelnic, Adrian
    Kaesmacher, Johannes
    Mujanovic, Adnan
    Meinel, Thomas R.
    Seiffge, David J.
    Heldner, Mirjam R.
    Liberman, Ava L.
    Navi, Babak B.
    Fischer, Urs
    Arnold, Marcel
    Jung, Simon
    Bucke, Philipp
    Beyeler, Morin
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (08):